Day One: 16 March 2005
9:00 AM BALLROOM: Chairman's Welcome Address: Dr. Kathleen Williams, Co-Chair, Life Sciences, Palmer & Dodge
9:15 AM Keynote: Life Science Start-ups: Exploring the Adjacent Probable
Dr Noubar B. Afeyan, Senior Managing Director & CEO, Flagship Ventures
9:35 AM Keynote Address: Bio Defense: recognising the need for new therapeutics
Steven St Peter, Partner, MPM Capital
10.20 AM Small-Cap Listed Company Presentations
  Ballroom:
SMALL CAP LISTED COMPANIES
Chair: Dr John Burt, Thiakis 		Venetian Room:
SMALL CAP LISTED COMPANIES
Chair: Richard Smith, Palmer & Dodge 		Ballroom Foyer:
SMALL CAP LISTED COMPANIES
Chair: Dr Yvonne Wegmann, SWX Swiss Exchange
10:25 AM MethylGene, Inc.
Donald F. Corcoran, President & CEO		 Avitar, Inc.
Peter Phildius, Chairman & CEO		 Emisphere Technologies
Dr Michael M Goldberg, Chairman & CEO
10:40 AM BioSante Pharmaceuticals, Inc.
Stephen Simes, CEO		 Norwood Abbey
Bernie Romanin, Senior Vice President Corporate Development		 Favrille, Inc
John Longenecker, President & CEO
10:55 AM MacroChem Corporation
Robert DeLuccia, President & CEO		 Biophan Technologies, Inc.
Michael Weiner, CEO		 Basilea Pharmaceutica
Dr Anthony Man, Chief Executive Officer
11:10 AM Palatin Technologies, Inc.
Dennis Earle, Executive Director		 Life Medical Sciences Inc
Robert P. Hickey, President & CEO		 Diamyd Medical
Anders Essen-Moller, Chief Executive Officer
11:25 AM Grant Life Sciences
Stan Yakatan, CEO		 Viventia Biotech Inc
Dr Nick Glover, President & CEO		 VioQuest
Daniel Greenleaf, President & CEO
11:40 AM YM BioSciences Inc.
David Allan, Chief Executive Officer		 NovaDel Pharma Inc.
Dr Gary A. Shangold, Chief Executive Officer		 Zeltia
Catherine Moukheibir, Director Capital Market Operations & Dr. Jose Jimeno, VP Scientific Development, PharmaMar
11:55 AM Curis, Inc.
Daniel Passeri, President & Chief Executive Officer		 Adherex Technologies Inc.
Dr William Peters, Chairman & CEO
12:10 PM Questions Questions Questions
1:45 PM Keynote Address
Dr Stelios Papdopoulos, Vice Chairman, SG Cowen Securities Corporation
2:05 PM Keynote: Overview of the European Capital Markets
Dr Heinrich Henckel, Chief Executive Officer, SWX Swiss Exchange
2:20 PM Keynote: Biotech Investing, now and then
Jean-François Formela, Senior Partner, Atlas Venture
3:05 PM Venture Funded Early to Mid Stage Company Presentations
  Ballroom:
IMMUNOLOGY/ONCOLOGY
Chair: Rhonda Chiger, RX IR Communications 		Venetian Room:
THERAPEUTICS
Chair: Donna LaVoie, LaVoie Strategic Communications Group 		Ballroom Foyer:
THERAPEUTICS
Chair: Ira Leiderman, The Trout Group
3:10 PM Avidex
James Noble, Chief Executive Officer		 Aderis Pharmaceuticals
Kenneth L. Rice, VP, CFO & Chief Commercial Officer  		 atugen AG
Thomas Christély, COO & CFO
3:25 PM ESBATech AG
Dr Dominik Escher, Chief Executive Officer		 Serenex
Ian Howes, Vice President & CFO		 Develogen
Dr Guenther Karmann, Chief Executive Officer
3:40 PM BioVex
Dr Tony Mills, VP Business Development		 ACE Biosciences
Ingelise Saunders, Chief Executive Officer 		EVOTEC Neurosciences
Dr John Kemp, Chief Executive Officer
3:55 PM  Oncomethylome Sciences
Dr Herman Spolders, Chief Executive Officer 		Psychiatric Genomics
Dr Richard Chipkin, President & CEO		 Sirtris Pharmaceuticals
Dr Christoph Westphal, Chief Executive Officer
4:10 PM Intercell
Prof Alexander von Gabain, Chief Executive Officer		 Ambit Biosciences
Bruce Steel, Corporate Development 		PBL Therapeutics
Robert Pestka, President & CEO
4:25 PM Aegera Therapeutics
Michael Atkin, Chief Executive Officer 		Lipocine Inc
Jerry Simmons, Corporate Business Development Officer		 MedExGen
Dr Yong-Hoon Chung, President & CEO
4:40 PM   NeuroMed Technologies
Dr Christopher C. Gallen, President & CEO		 Ablynx
Dr Mark Vaeck, Chief Executive Officer

Day Two: 17 March 2005
8:45 AM BALLROOM: Chairman's Welcome Address: Mark R. Saunders, President, Global Markets Capital Group LLC
9:00 AM Panel Discussion: Venture Financing the way forward
Chair: Michael Lytton, General Partner, Oxford Bioscience Partners
Discussants: Jonathan Leff, Managing Director, Warburg Pincus
David Milne, General Partner, SV Life Science Advisors
9:45 AM Keynote Address
G. Steven Burrill, Chief Executive Officer, Burrill & Co.
  Venture Funded Early to Mid Stage Company Presentations
10:15 AM Ballroom: Immunology/Oncology: Dr. Anil Khurana, Access International
Chair: Dr Anil Khurana, Access International 		Venetian Room: Therapeutics
Chair: Christine Labaree, The Trout Group
10:20 AM Aureon Biosciences Corp
Vijay Aggarwal, CEO & President		 Amphora Discovery Corp
Peter G. Savas, Chairman & Acting CEO
10:35 AM Librophyt
Alain Tissier, Chief Executive Officer		 BioLine RX
Dr Morris Laster, Chief Executive Officer
10:50 AM Pieris ProteoLab
Dr Martin Poehlchen, Chief Executive Officer 		Medicago
Andy Sheldon, President & CEO
11:05 AM Topigen Pharmaceuticals
Dr Paul Wotton, President & CEO		 TransPharma Medical
Dr Daphna Heffetz, Chief Executive Officer
11:20 AM Xanthus Life Sciences
Richard Dean, Chief Executive Officer 		Scil Technology
Dr Irina Staatz-Granzer, Managing Director
11:35 AM Perlegen
Robert Middlebrook, Chief Corporate Development Officer 		Arrow Therapeutics Ltd.
Ian Garland, Chief Financial Officer
11:50 AM   Polymedix Inc
Nick Landekic, President & CEO
12:05 AM Questions Questions
1:45 PM
Panel Discussion: Why is Medtech attracting new investment
Chair:

William C Mills III, Managing Member, EGS Healthcare Capital Partners
Discussants: Marc Goldberg, Managing Director, BioVentures Investors
Jan Wald, Analyst, AG Edwards & Sons
Dr Lothar Krinke, Senior Director BioSciences Technology Development, Medtronic
Mark Chalek, Chief, Business Ventures, Beth Israel Deaconess Medical Centre
3:00 PM
Panel Discussion: Bio Partnering and Collaborations between Pharmas and Biotechs
Chair: Dr Maggie Flanagan, Global Alliance Director, Enabling Science & Technology, AstraZeneca
Discussants: Dr Klaus Wilgenbus, Head of Corporate Division, Licensing, Boehringer Ingelheim
Dr Robert Gould, Vice President, External Scientific Affairs Worldwide, Merck & Co
Steve Twait, Alliance Management, Eli Lilly & Co
4:00 PM Concluding Presentation: Global Themes - Looking Ahead to 2006 and Beyond
Stan Yakatan, Chairman, Katan Associates
4:20 PM
Close of Conference